MedTrace Logo

Understanding Disparities in Quitting in African American and White Smokers

NCT01836276 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 449

Last updated 2018-10-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the differences in quitting smoking between African Americans (AA) and White smokers treated with varenicline.

Conditions

  • Smoking Cessation

Interventions

DRUG

Varenicline

1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Pfizer

    collaborator INDUSTRY

  • Nikki Nollen, PhD, MA

    lead OTHER

Principal Investigators

  • Nikki Nollen, PhD, MA · University of Kansas Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01836276 on ClinicalTrials.gov